Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.

Neuro-oncology - 1 Nov 2012

Piao Yuji, Liang Ji, Holmes Lindsay, Zurita Amado J, Henry Verlene, Heymach John V, de Groot John F

Abstract excerpt

Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis. Inhibiting the VEGF-VEGF receptor (R) signal transduction pathway in glioblastoma has recently been shown to delay progression, but the relative benefit and mechanisms of response and failure of anti-VEGF therapy a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab
Share to Cell Hypoxia
Share to Mesoderm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloid Cells

Share to Neovascularization, Pathologic

Share to Pyrroles

Share to Receptors, Vascular Endothelial Growth Factor

Share to Sunitinib

Source

Open in PubMed Open full text

Identifiers

PMID: 22965162
DOI: 10.1093/neuonc/nos158
PMCID: PMC3480262

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22965162-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.PMID 22965162Read ↗

Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.Semantic proximity Read ↗

Immune Cell Interplay in the Fight Against GBMSemantic proximity Read ↗

Tumor vasculature and glioma stem cells: Contributions to glioma progression.Semantic proximity Read ↗

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.Semantic proximity Read ↗

Paradoxical role of β8 integrin on angiogenesis and vasculogenic mimicry in glioblastomaSemantic proximity Read ↗

Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastomaSemantic proximity Read ↗

Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy ResistanceSemantic proximity Read ↗

VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cellsSemantic proximity Read ↗

Genetic and hypoxic regulation of angiogenesis in gliomas.Semantic proximity Read ↗

Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas.Semantic proximity Read ↗

Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.Semantic proximity Read ↗

Neutrophils promote the malignant glioma phenotype through S100A4.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.